Cancer Stem Cell News Volume 10.47 | Dec 1 2021

    0
    24







    2021-12-01 | CSCN 10.47


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.47 – 1 December, 2021
    TOP STORY

    Aptamer-Mediated Doxorubicin Delivery Reduces HCC Burden in 3D Organoids Model

    Researchers developed a specific aptamer against epithelial cell adhesion molecule and tested its potential as a drug delivery agent for hepatocellular carcinoma (HCC).
    [Journal of Controlled Release]

    AbstractGraphical Abstract

    Explore scientific events this December with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    Chemotoxicity-Induced Exosomal lncFERO Regulates Ferroptosis and Stemness in Gastric Cancer Stem Cells

    Investigators showed that stearoyl-CoA-desaturase played a key role in regulating lipid metabolism and ferroptosis in gastric cancer stem cells.
    [Cell Death & Disease]

    Full Article

    Elevated ATGL in Colon Cancer Cells and Cancer Stem Cells Promotes Metabolic and Tumorigenic Reprogramming Reinforced by Obesity

    Elevated adipose triglyceride lipase (ATGL) levels in human colon cancer cells relative to non-transformed were augmented by an obesity mediator, oleic acid.
    [Oncogenesis]

    Full Article

    NIR Irradiation Enhances the Apoptotic Potentiality of Quinacrine-Gold Hybrid Nanoparticles by Modulation of HSP-70 in Oral Cancer Stem Cells

    Using in vitro oral squamous cell carcinoma CSCs and in vivo xenograft mice model, the authors systematically studied the apoptotic potentiality of Quinacrine-gold hybrid nanoparticle and its underlying mechanism after near-infrared radiation (NIR) irradiation.
    [Nanomedicine-Nanotechnology Biology and Medicine]

    AbstractGraphical Abstract

    Spatial Heterogeneity of Invading Glioblastoma Cells Regulated by Paracrine Factors

    Scientists observed spatially heterogeneous glioblastoma cell populations emerge from an isogenic clonal population of glioma-initiating cells during invasion into a 3D collagen hydrogel in a microfluidic device.
    [Tissue Engineering Part A]

    Abstract

    Targeting Alpha-2,3-Sialylated Glycan in Glioma Stem-Like Cells by Maackia amurensis Lectin-II: A Promising Strategy for Glioma Treatment

    Researchers established a new glioma stem-like cell, named U373-GSC, from the U373 glioma cell line. The cells exhibited stemness properties such as the expression of stem cell markers, self-renewal activity, multi-lineage differentiating abilities, and drug resistance.
    [Experimental Cell Research]

    Abstract

    MiR-342-3p Inhibits LCSC Oncogenicity and Cell Stemness through HDAC7/PTEN Axis

    miR-342-3p overexpression in liver CSCs (LCSC) led to lower tumor volume, reduced tumor spheroid formation, and agar colony formation rates, as well as lower mRNA and protein expressions of CD44, ALDH1, Bmi1, Sox2, and Oct4.
    [Inflammation Research]

    Abstract

    pERK-Mediated IL8 Secretion Can Enhance the Migration, Invasion, and Cisplatin Resistance of CD10-Positive Oral Cancer Cells

    Scientists hypothesized that IL8 may have regulated migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells through the ERK pathway.
    [BMC Cancer]

    Full Article

    Survey results on the needs and challenges in the human pluripotent stem cell field
    REVIEWS

    Targeting the Metabolism of Cancer Stem Cells by Energy Disruptor Molecules

    Investigators highlight the differences between regular cancer cells and CSC metabolism and discuss the action mechanisms of energy disruptors at the cellular and molecular levels.
    [Critical Reviews in Oncology/Hematology]

    AbstractGraphical Abstract

    Advances in Glioma-Associated Oncogene (GLI) Inhibitors for Cancer Therapy

    The authors review direct and indirect inhibitors of GLI and summarize the abundant active structurally diverse natural GLI inhibitors.
    [Investigational New Drugs]

    Abstract

    INDUSTRY AND POLICY NEWS

    Kura Oncology Provides Update on Phase Ib Study of KO-539 in Acute Myeloid Leukemia

    Kura Oncology, Inc. announced that the US FDA has placed the KOMET-001 Phase Ib study of KO-539 in patients with relapsed or refractory acute myeloid leukemia on a partial clinical hold following the company’s recent report of a Grade 5 serious adverse event potentially associated with differentiation syndrome.
    [Kura Oncology, Inc.]

    Press Release

    International Collaboration Secures €1M Grant to Investigate New Treatment Target for Lymphoma

    An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.
    [News Medical Life Sciences]

    Press Release

    FEATURED EVENT

    AACR: Targeting RAS

    January 7 – 10, 2022
    Lake Buena Vista, Florida, United States

    > See All Events

    JOB OPPORTUNITIES

    Professors – Synthetic Biology in Cancer Immunotherapy

    The University of Chicago – Chicago, Illinois, United States

    Faculty Positions – Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine

    Stanford University – Palo Alto, California, United States

    Research Scientists – Stem Cells and Organoids

    RIKEN – Hirosawam, Japan

    Staff Scientist/Research Associate – Cancer Research

    Fred Hutchinson Cancer Research Center – Seattle, Washington, United States

    Postdoctoral Fellow – Cancer Biology and Metabolism

    German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter